Pilgrim Partners Asia Pte Ltd Invests $67,000 in Moderna, Inc. (NASDAQ:MRNA)

Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 1,600 shares of the company’s stock, valued at approximately $67,000.

A number of other hedge funds also recently made changes to their positions in the stock. Resona Asset Management Co. Ltd. bought a new position in shares of Moderna in the fourth quarter worth approximately $3,920,000. Prudential PLC raised its holdings in Moderna by 122.5% during the fourth quarter. Prudential PLC now owns 12,210 shares of the company’s stock valued at $508,000 after acquiring an additional 6,722 shares during the period. Annis Gardner Whiting Capital Advisors LLC lifted its position in shares of Moderna by 15.4% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 5,441 shares of the company’s stock valued at $226,000 after acquiring an additional 725 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in shares of Moderna during the fourth quarter worth about $3,658,000. Finally, World Investment Advisors bought a new stake in Moderna during the 4th quarter valued at approximately $295,000. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MRNA has been the topic of several recent analyst reports. Bank of America reduced their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. UBS Group cut their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Berenberg Bank boosted their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Finally, Leerink Partners cut their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and an average price target of $59.00.

Moderna Stock Performance

NASDAQ MRNA opened at $25.11 on Friday. Moderna, Inc. has a one year low of $23.76 and a one year high of $170.47. The company has a market capitalization of $9.71 billion, a price-to-earnings ratio of -2.71 and a beta of 2.23. The company’s 50-day simple moving average is $33.55 and its two-hundred day simple moving average is $43.01.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.